Back to top
more

Veeva Systems (VEEV)

(Delayed Data from NYSE)

$204.67 USD

204.67
466,941

+0.14 (0.07%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 251)

Industry: Internet - Software

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to gain from its Mako robotics platform, which has been the key driver of the company's core Orthopaedic segment.

Is Veeva Systems (VEEV) a Great Growth Stock?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Veeva Systems (VEEV).

Walgreens (WBA) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Walgreens' (WBA) retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market.

Walgreens-Alphabet Join Forces to Control Healthcare Costs

by Zacks Equity Research

Walgreens (WBA) and Alphabet's arm Verily to start a medication adherence pilot project that will deploy equipment and other methods to improve adherence.

Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base

by Zacks Equity Research

Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.

Veeva Systems (VEEV) Stock Moves -0.88%: What You Should Know

by Zacks Equity Research

In the latest trading session, Veeva Systems (VEEV) closed at $87.08, marking a -0.88% move from the previous day.

Here's Why You Should Invest in STERIS (STE) Stock Right Now

by Zacks Equity Research

With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.

Abercrombie, Halliburton, Veeva, Attunity and Nice highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Abercrombie, Halliburton, Veeva, Attunity and Nice highlighted as Zacks Bull and Bear of the Day

Medtronic's Mazor Buyout Creates a New Spine Surgery Major

by Zacks Equity Research

With the acquisition of Mazor Robotics, Medtronic (MDT) expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation.

Ryan McQueeney headshot

3 Cloud Stocks to Buy Right Now

by Ryan McQueeney

In a matter of just a few years, "the Cloud" has evolved from a budding new tech feature to one of the main factors driving growth in the technology sector. Check out these three cloud stocks to buy right now!

Veeva, Party City, Mellanox, Cree and Intel highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Veeva, Party City, Mellanox, Cree and Intel highlighted as Zacks Bull and Bear of the Day

GNC Holdings Global Business Strong, Same Store Sales Weak

by Zacks Equity Research

GNC Holdings' (GNC) domestic franchise revenues worsen due to soft retail same store sales and fewer franchise stores.

Here's Why You Should Buy Haemonetics (HAE) Stock Right Now

by Zacks Equity Research

Haemonetics (HAE) continues to witness strong growth in Plasma franchise.

Madeleine Johnson headshot

Bull of the Day: Veeva Systems (VEEV)

by Madeleine Johnson

Estimates are swinging higher for this booming SaaS stock.

Sweta Jaiswal headshot

4 Medical Device Stocks That More Than Doubled in 2018

by Sweta Jaiswal

Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.

Hologic's (HOLX) New Offering to Revitalize Cynosure Division

by Zacks Equity Research

The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.

Bruker Profits from NANO & CALID, New Buyout Holds Promise

by Zacks Equity Research

Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.

Veeva Systems (VEEV) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Veeva Systems (VEEV) closed the most recent trading day at $92.13, moving +0.1% from the previous trading session.

Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength

by Zacks Equity Research

We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.

Edwards Lifesciences Advances in AI With Bay Labs Tie-Up

by Zacks Equity Research

Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.

CVS Health Aetna Synergy Impressive, PBM Selling Season Solid

by Zacks Equity Research

CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.

STERIS Rides on Favorable Industry Trends, Rivalry a Concern

by Zacks Equity Research

STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.

NuVasive's Monolith Corpectomy System Ok'd for Expanded Use

by Zacks Equity Research

NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.

Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm

by Zacks Equity Research

Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.

Hill-Rom Adds New Capabilities to Centrella Smart+ Beds

by Zacks Equity Research

Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.